Intérêt du dosage des marqueurs angiogéniques et antiangiogéniques dans la prise en charge de la prééclampsie [Clinical value of angiogenic and anti-angiogenic marker assay in preeclampsia]

Details

Serval ID
serval:BIB_4BEC3918D36E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Intérêt du dosage des marqueurs angiogéniques et antiangiogéniques dans la prise en charge de la prééclampsie [Clinical value of angiogenic and anti-angiogenic marker assay in preeclampsia]
Journal
Revue medicale suisse
Author(s)
Mccarey C., Baert J., Mathey M.P., Martinez De Tejada B., Vial Y., Berkane N., Rieder W.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
28/10/2020
Peer-reviewed
Oui
Volume
16
Number
712
Pages
2031-2036
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Abstract
Preeclampsia is a disease which originates in the placenta and is specific to human pregnancy. It is one of the main causes of maternal and perinatal morbidity and mortality. The introduction of assays for angiogenic and anti-angiogenic markers reflecting placental dysfunction, which lies at the root of preeclampsia, is a turning point in the management of women with suspected preeclampsia or with an atypical form of the disease. The sFlt1/PlGF ratio assay, which has been covered by health insurance since July 2019, is a valuable diagnostic aid : the disease can be ruled out, with a high negative predictive value, when the ratio is low, thus avoiding unnecessary hospital admission and premature delivery. A high ratio can help to confirm the diagnosis of preeclampsia, albeit with a lower positive predictive value.
Pubmed
Create date
02/11/2020 12:29
Last modification date
09/01/2021 6:26
Usage data